Table 4.
Thrombotic events in ICU
| No. of thrombotic events—no (%) | 11 | (9) |
| Site of thrombosis | ||
| Brain | 5 | |
| Arm, fingers, toes | 2 | |
| Liver veins | 2 | |
| Spleen (post-mortem finding) | 1 | |
| Inferior vena cava | 1 | |
| Haematological diagnosis | ||
| AML | 10 | |
| ALL | 1 | |
| MDS | 0 | |
| Severe sepsis/septic shock—no (%) | 11 | (100) |
| Death directly related to thrombosis—no | 4 | |
| Bleeding prior to thrombotic event | 3 | |
| Bleeding after thrombotic event | 3 | |
| LMWHa | 4 | |
| Drugs given prior to thrombotic event | ||
| Tranexamic acid | 2 | b |
| Vitamin K | 2 | c |
Data are in number (%)
AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia, MDS myelodysplastic syndrome, LMWH low molecular weight heparin
aEnoxaparin 20–40 mg daily in ICU before thrombotic event
bSite of thrombi: 1. spleen (post-mortem finding); 2. thalamus (MRI finding)
cSite of thrombi: 1. inferior vena cava; 2. brain (multiple sites)